AI-Driven Antimicrobial Peptide Discovery: Mining and Generation

Paulina Szymczak, Wojciech Zarzecki, Jiejing Wang, Yiqian Duan, Jun Wang, Luís Pedro Coelho, César de la Fuente‐Núñez, Ewa Szczurek

TL;DR

The escalating threat of antimicrobial resistance (AMR) demands novel therapeutic strategies, and antimicrobial peptides (AMPs) offer a promising avenue. This paper reviews how Artificial Intelligence (AI), through mining existing biological sequences and generating novel ones, is revolutionizing AMP discovery, accelerating the identification of potent and safe candidates.

What Problem Does This Paper Address?

The world is facing a growing crisis of antimicrobial resistance (AMR), where traditional antibiotics are becoming increasingly ineffective. Discovering new antibiotic classes has slowed dramatically in recent decades, creating an urgent need for innovative approaches. Antimicrobial peptides (AMPs) are a natural defense mechanism found in many organisms, showing selectivity for bacterial membranes and a slower induction of resistance compared to conventional antibiotics. However, the sheer vastness of possible peptide sequences (the "sequence space") makes traditional discovery methods incredibly inefficient. Designing effective AMPs that are both potent against bacteria and safe for human cells (low toxicity) is a major challenge. This paper addresses this challenge by exploring how AI can navigate this complex sequence space to identify and design novel AMPs.

Methods

The paper highlights two primary AI-driven strategies for AMP discovery:

  • AMP Mining: This involves using AI to scan vast biological sequence databases (like genomes and proteomes) to identify potential AMP candidates. Discriminative models are then employed to predict the activity and toxicity of these identified peptides. This approach leverages existing biological data to find naturally occurring or evolutionarily conserved AMPs.
  • AMP Generation: This strategy uses generative AI models to create entirely new peptide sequences. These models learn patterns from existing AMP data and then generate novel sequences optimized for desired properties, such as high antimicrobial activity and low toxicity. This allows for the design of synthetic peptides that might surpass naturally occurring ones.

The paper also emphasizes the crucial role of discriminative methods as a "toolbox" for both mining and generation. These methods, often based on deep learning architectures like Recurrent Neural Networks (RNNs), Long Short-Term Memory (LSTM) networks, and more recently, Large Language Models (LLMs) adapted for protein sequences (Protein Language Models or PLMs), are used to classify peptides as AMPs or non-AMPs, predict their minimum inhibitory concentration (MIC), or assess their toxicity.

Datasets

The paper discusses the use of various biological sequence collections for AMP mining and generation:

  • Genomes, Proteomes, and Metagenomes: These are vast repositories of genetic and protein information from diverse organisms and microbial communities. Examples include the nonredundant Global Microbial Gene Catalogue (GMGCv1) and the Global Microbiome Catalog of Small Open Reading Frames (GMSC).
  • Human Proteome: Explored as a source of potential AMPs.
  • Extinct Organisms: Efforts have been made to mine sequences from extinct species (e.g., Neanderthals) for novel antimicrobials ("molecular de-extinction").
  • Microbiome Data: Specifically, the human gut microbiome and microbiomes from other organisms (e.g., Hydra, cockroaches) have been mined.
  • Existing AMP Databases: Datasets like DBAASP are mentioned as resources for experimentally validated AMPs.

The paper does not explicitly introduce a new benchmark dataset but discusses the need for more comprehensive datasets, particularly those including experimentally validated negative examples (non-AMPs) and data on peptide toxicity.

Key Insights and Ideas

  • AI as a Navigator of Complexity: The immense sequence space of peptides makes brute-force discovery impossible. AI, particularly deep learning and LLMs, provides the necessary tools to efficiently explore this space.
  • Realism vs. Idealism in Design: AMP mining tends to find "realistic" peptides (those that resemble natural ones), while AMP generation can create "idealistic" peptides (optimized for properties, potentially novel). Balancing these two is key.
  • The Power of Transfer Learning: Pretrained LLMs, originally developed for natural language, are being adapted for protein and peptide sequences, significantly boosting prediction accuracy and reducing the need for massive, specific training datasets.
  • Toxicity Prediction is a Major Hurdle: While AMP activity prediction is advancing, accurately predicting peptide toxicity remains a significant challenge, hindering clinical translation.
  • Data Scarcity and Quality are Critical: The effectiveness of AI models is heavily dependent on the availability and quality of experimental data, especially for negative examples and toxicity profiles.

Key Results

The paper highlights successful applications of AI in AMP discovery:

  • Identification of Promising Candidates: Both mining and generation approaches have successfully identified numerous AMP candidates that have been validated experimentally, some showing efficacy in preclinical models.
  • Accelerated Discovery: AI has drastically reduced the time required for AMP discovery, transforming a process that once took years into one that can be completed in hours.
  • Discovery of Novel AMPs: AI has enabled the discovery of novel AMPs, including those from previously unexplored sources like extinct organisms and the human proteome, and even synthetic peptides with properties potentially superior to natural ones.
  • Examples of Successful Models: The paper references specific AI models and their achievements, such as HydrAMP discovering 15 novel, potent AMPs, and APEX identifying preclinical candidates from extinct organisms.

Limitations and Future Work

  • Data Scarcity and Quality: A major limitation is the relatively small volume of available experimental data, especially for toxicity and negative examples. Future work should focus on initiatives for data sharing and standardizing experimental validation.
  • Toxicity Prediction: Current methods for predicting peptide toxicity are suboptimal. More research is needed to develop robust toxicity predictors.
  • Handling Modified Peptides: Most current AI models are limited to the standard 20 amino acid alphabet and struggle with chemically modified or non-canonical peptides, which are common in clinically relevant AMPs. Future work should focus on incorporating these modifications.
  • Structural Information: While progress is being made, fully leveraging peptide structural information (beyond sequence) for functional prediction remains an area for development.
  • Robustness and Generalizability: Existing AI models need to be objectively evaluated on independent datasets to ensure their robustness and generalizability.
  • Benchmarking Generative Models: Evaluating and benchmarking generative models for AMPs is challenging due to the difficulty in assessing novelty, diversity, and actual activity/toxicity without extensive experimental validation.
  • Clinical Translation: While many promising candidates have been identified, few have progressed to clinical trials. This highlights the need for collaborative efforts between AI, chemical, and biological labs, along with industrial partners, to bridge the gap from discovery to clinic.
  • Beyond Linear Peptides: Future research should explore generating and mining for complex, modified peptides, and incorporating data on peptide stability and ADMET properties.

Summary updated

Abstract

ConspectusThe escalating threat of antimicrobial resistance (AMR) poses a significant global health crisis, potentially surpassing cancer as a leading cause of death by 2050. Traditional antibiotic discovery methods have not kept pace with the rapidly evolving resistance mechanisms of pathogens, highlighting the urgent need for novel therapeutic strategies. In this context, antimicrobial peptides (AMPs) represent a promising class of therapeutics due to their selectivity toward bacteria and slower induction of resistance compared to classical, small molecule antibiotics. However, designing effective AMPs remains challenging because of the vast combinatorial sequence space and the need to balance efficacy with low toxicity. Addressing this issue is of paramount importance for chemists and researchers dedicated to developing next-generation antimicrobial agents.Artificial intelligence (AI) presents a powerful tool to revolutionize AMP discovery. By leveraging AI, we can navigate the immense sequence space more efficiently, identifying peptides with optimal therapeutic properties. This Account explores the emerging application of AI in AMP discovery, focusing on two primary strategies: AMP mining, and AMP generation, as well as the use of discriminative methods as a valuable toolbox.AMP mining involves scanning biological sequences to identify potential AMPs. Discriminative models are then used to predict the activity and toxicity of these peptides. This approach has successfully identified numerous promising candidates, which were subsequently validated experimentally, demonstrating the potential of AI in AMP design and discovery.AMP generation, on the other hand, creates novel peptide sequences by learning from existing data through generative modeling. This class of models optimizes for desired properties, such as increased activity and reduced toxicity, potentially producing synthetic peptides that surpass naturally occurring ones. Despite the risk of generating unrealistic sequences, generative models hold the promise of accelerating the discovery of highly effective and highly novel and diverse AMPs.In this Account, we describe the technical challenges and advancements in these AI-based approaches. We discuss the importance of integrating various data sources and the role of advanced algorithms in refining peptide predictions. Additionally, we highlight the future potential of AI to not only expedite the discovery process but also to uncover peptides with unprecedented properties, paving the way for next-generation antimicrobial therapies.In conclusion, the synergy between AI and AMP discovery opens new frontiers in the fight against AMR. By harnessing the power of AI, we can design novel peptides that are both highly effective and safe, offering hope for a future where AMR is no longer a looming threat. Our paper underscores the transformative potential of AI in drug discovery, advocating for its continued integration into biomedical research.
BibTeX
@inproceedings{szymczak2025ai,
  author = {Paulina Szymczak and Wojciech Zarzecki and Jiejing Wang and Yiqian Duan and Jun Wang and Luís Pedro Coelho and César de la Fuente‐Núñez and Ewa Szczurek},
  title = {{AI-Driven Antimicrobial Peptide Discovery: Mining and Generation}},
  booktitle = {Accounts},
  year = {2025},
  doi = {10.1021/acs.accounts.0c00594},
}
Figure